{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T20:09:01Z","timestamp":1776110941792,"version":"3.50.1"},"reference-count":116,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1826,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Highly active antiretroviral therapy (HAART)-related hepatotoxicity complicates the management of patients infected with human immunodeficiency virus (HIV), increases medical costs, alters the prescription patterns, and affects the guideline recommendations. Among the clinical consequences derived from HAART-related liver toxicity, hypersensitivity reactions and lactic acidosis are recognized as acute events with potential to evolve into fatal cases, whereas there seems to be other syndromes not as well characterized but of equal concern as possible long-term liver complications. Belonging to the latter category of syndrome, HAART-related nonalcoholic steatohepatitis, liver fibrosis, portal hypertension, and nodular regenerative hyperplasia are discussed in this review. Updated information on liver toxicity of current antiretroviral drugs, including the most recently licensed, is provided. Management and prevention of liver toxicity among HIV-infected patients treated with HAART are reviewed as well.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.23716","type":"journal-article","created":{"date-parts":[[2010,4,14]],"date-time":"2010-04-14T23:36:38Z","timestamp":1271288198000},"page":"1143-1155","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":143,"title":["Clinical Syndromes and Consequences of Antiretroviral-Related Hepatotoxicity5, 1, 3"],"prefix":"10.1097","volume":"52","author":[{"given":"Marina","family":"N\u00fa\u00f1ez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-36-20250312","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00002018-200528010-00004","article-title":"Hepatotoxicity of antiretrovirals: incidence, mechanisms and management.","volume":"28","author":"Nunez","year":"2005","journal-title":"Drug Safety"},{"key":"R2-36-20250312","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.jhep.2005.11.027","article-title":"Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management.","volume":"44","author":"Nunez","year":"2006","journal-title":"J Hepatol"},{"key":"R3-36-20250312","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.dld.2006.01.020","article-title":"Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.","volume":"38","author":"Bruno","year":"2006","journal-title":"Dig Liver Dis"},{"key":"R4-36-20250312","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/jac\/dkl524","article-title":"Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.","volume":"59","author":"Rivero","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R5-36-20250312","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.cld.2007.06.008","article-title":"Drug-induced liver injury associated with HIV medications.","volume":"11","author":"Jain","year":"2007","journal-title":"Clin Liver Dis"},{"key":"R6-36-20250312","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0b013e3282f0e2fd","article-title":"Antiretroviral drugs and liver injury.","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"key":"R7-36-20250312","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/157488608783333916","article-title":"Highly active antiretroviral therapy-induced liver injury.","volume":"3","author":"Inductivo-Yu","year":"2008","journal-title":"Curr Drug Saf"},{"key":"R8-36-20250312","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-2003-39949","article-title":"Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors.","volume":"23","author":"Sulkowski","year":"2003","journal-title":"Semin Liver Dis"},{"key":"R10-36-20250312","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/gut.2008.163675","article-title":"Diagnosis, management and prevention of drug-induced liver injury.","volume":"58","author":"Verma","year":"2009","journal-title":"Gut"},{"key":"R12-36-20250312","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"R13-36-20250312","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease.","volume":"42","author":"Bjornsson","year":"2005","journal-title":"Hepatology"},{"key":"R14-36-20250312","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.","volume":"35","author":"Sulkowski","year":"2002","journal-title":"Hepatology"},{"key":"R15-36-20250312","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00126334-200108150-00002","article-title":"Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.","volume":"27","author":"Nunez","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R16-36-20250312","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.qai.0000243054.58074.59","article-title":"Predictors of antiretroviral-related hepatotoxicity in the Adults AIDS Clinical Trial Group (1989-1999).","volume":"43","author":"Servoss","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R17-36-20250312","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/341084","article-title":"Incidence of and risk factors for severe hepatotoxicity assocated with antiretroviral combination therapy.","volume":"186","author":"Wit","year":"2002","journal-title":"J Infect Dis"},{"key":"R18-36-20250312","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1086\/649922","article-title":"Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.","volume":"50","author":"Kovari","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R19-36-20250312","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2174\/092986709788803097","article-title":"Current concepts of mechanisms in drug-induced hepatotoxicity.","volume":"16","author":"Russmann","year":"2009","journal-title":"Curr Med Chem"},{"key":"R20-36-20250312","first-page":"489","article-title":"Idiosyncratic drug hepatotoxicity.","volume":"4","author":"Kaplowitz","year":"2005","journal-title":"Nature Rev"},{"key":"R21-36-20250312","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/toxsci\/kfl180","article-title":"Troglitazone induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities.","volume":"97","author":"Ong","year":"2007","journal-title":"Toxicol Sci"},{"key":"R22-36-20250312","doi-asserted-by":"crossref","first-page":"13565","DOI":"10.1074\/jbc.M708916200","article-title":"Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury.","volume":"283","author":"Hanawa","year":"2008","journal-title":"J Biol Chem"},{"key":"R23-36-20250312","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.pharmtox.43.100901.140229","article-title":"Regulatory mechanisms controlling gene expression mediated by the antioxidant response element.","volume":"43","author":"Nguyen","year":"2003","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R24-36-20250312","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1055\/s-2007-991513","article-title":"Endoplasmic reticulum stress and liver injury.","volume":"27","author":"Kaplowitz","year":"2007","journal-title":"Semin Liver Dis"},{"key":"R26-36-20250312","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cbi.2004.09.002","article-title":"Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor.","volume":"150","author":"Ganey","year":"2004","journal-title":"Chem Biol Interact"},{"key":"R27-36-20250312","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cld.2007.06.001","article-title":"Mechanisms of drug-induced liver disease.","volume":"11","author":"Gunawan","year":"2007","journal-title":"Clin Liver Dis"},{"key":"R28-36-20250312","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1086\/597276","article-title":"Immunopathogenesis of hepatic flare in HIVHepatitis B Virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy.","volume":"199","author":"Crane","year":"2009","journal-title":"J Infect Dis"},{"key":"R29-36-20250312","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/01.mjt.0000162013.66614.16","article-title":"Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk.","volume":"13","author":"Barbaro","year":"2006","journal-title":"Am J Ther"},{"key":"R30-36-20250312","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-2003-39947","article-title":"Hepatotoxicity of nucleoside reverse transcriptase inhibitors.","volume":"23","author":"Montessori","year":"2003","journal-title":"Semin Liver Dis"},{"key":"R38-36-20250312","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1097\/00002030-200411190-00008","article-title":"Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.","volume":"18","author":"Sulkowski","year":"2004","journal-title":"AIDS"},{"key":"R39-36-20250312","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1089\/aid.2006.0178","article-title":"Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.","volume":"23","author":"Gathe","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R40-36-20250312","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/324353","article-title":"Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.","volume":"33","author":"Boubaker","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R41-36-20250312","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1097\/QAD.0b013e3282f08cdc","article-title":"Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy.","volume":"21","year":"2007","journal-title":"AIDS"},{"key":"R42-36-20250312","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.qai.0000174649.51084.46","article-title":"Risk factors for symptomatic mitochondrial toxicity in HIVhepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.","volume":"40","author":"Bani-Sadr","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R59-36-20250312","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1053\/jhep.2001.23505","article-title":"Drug-induced liver injury: mechanisms and test systems.","volume":"33","author":"Bissell","year":"2001","journal-title":"Hepatology"},{"key":"R60-36-20250312","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/j.1572-0241.2001.03779.x","article-title":"Jaundice and hepatocellular damage associated with nevirapine therapy.","volume":"96","author":"Prakash","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R61-36-20250312","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1001\/archinte.161.20.2501","article-title":"DRESS sindrome associated with nevirapine therapy.","volume":"161","author":"Alonso","year":"2001","journal-title":"Arch Intern Med"},{"key":"R62-36-20250312","first-page":"222","article-title":"A near-fatal hypersensitivity reaction to abacavir: case report and literature review.","volume":"11","author":"Shapiro","year":"2001","journal-title":"AIDS Read"},{"key":"R63-36-20250312","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1086\/339751","article-title":"Abacavir hypersensitivity reaction.","volume":"34","author":"Hewitt","year":"2002","journal-title":"Clin Infect Dis"},{"key":"R64-36-20250312","doi-asserted-by":"crossref","first-page":"146","DOI":"10.7326\/0003-4819-137-2-200207160-00025","article-title":"Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen.","volume":"137","author":"Johnson","year":"2002","journal-title":"Ann Intern Med"},{"key":"R65-36-20250312","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/QAD.0b013e32832d3b54","article-title":"Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.","volume":"23","author":"Kesselring","year":"2009","journal-title":"AIDS"},{"key":"R66-36-20250312","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00002030-199606000-00009","article-title":"A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.","volume":"10","author":"Carr","year":"1996","journal-title":"AIDS"},{"key":"R67-36-20250312","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jama.279.12.930","article-title":"A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.","volume":"279","author":"Montaner","year":"1998","journal-title":"JAMA"},{"key":"R68-36-20250312","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.7326\/0003-4819-124-12-199606150-00001","article-title":"Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.","volume":"124","author":"DAquila","year":"1996","journal-title":"Ann Intern Med"},{"key":"R69-36-20250312","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/428093","article-title":"Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.","volume":"191","author":"Sanne","year":"2005","journal-title":"J Infect Dis"},{"key":"R70-36-20250312","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B5701 screening for hypersensitivity to abacavir.","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"R71-36-20250312","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/135965350801300508","article-title":"Incidence of abacavir hypersensitivity reactions in euroSIDA.","volume":"13","author":"Bannister","year":"2008","journal-title":"Antivir Ther"},{"key":"R72-36-20250312","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1345\/aph.1K574","article-title":"Efavirenz-induced hypersensitivity reaction manifesting in rash and hepatitis in a latino male.","volume":"42","author":"Leung","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R73-36-20250312","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/jac\/dkn548","article-title":"A pediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation.","volume":"63","author":"Turkova","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R74-36-20250312","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/QAD.0b013e328011aa35","article-title":"Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavirritonavir regimen.","volume":"21","author":"Pavel","year":"2007","journal-title":"AIDS"},{"key":"R75-36-20250312","first-page":"346","article-title":"Liver toxicity warning for darunavir.","volume":"22","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"R77-36-20250312","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLADRB1 0101 and abrogated by low CD4 T-cell counts.","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"},{"key":"R78-36-20250312","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/01.aids.0000238408.82947.09","article-title":"HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.","volume":"20","author":"Littera","year":"2006","journal-title":"AIDS"},{"key":"R79-36-20250312","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAD.0b013e32801199d9","article-title":"HLA-Cw8 primarily associated with hypersensitivity to nevirapine.","volume":"21","author":"Gatanaga","year":"2007","journal-title":"AIDS"},{"key":"R80-36-20250312","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1468-1293.2008.00552.x","article-title":"Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.","volume":"9","author":"De Lazzari","year":"2008","journal-title":"HIV Med"},{"key":"R81-36-20250312","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1086\/528861","article-title":"Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: The ATHENA Cohort Study.","volume":"46","author":"Wit","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R82-36-20250312","first-page":"1153","article-title":"Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-worldwide, 1997-2000.","volume":"49","year":"2001","journal-title":"MMWR"},{"key":"R83-36-20250312","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"R84-36-20250312","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1086\/529382","article-title":"High sensitivity of human leukocyte antigen-b5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.","volume":"46","author":"Saag","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R85-36-20250312","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/sti.79.4.340","article-title":"Lactic acidosis in HIV infected patients: a systematic review of published cases.","volume":"79","author":"Arenas-Pinto","year":"2003","journal-title":"Sex Transm Infect"},{"key":"R86-36-20250312","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/00002030-200207050-00005","article-title":"Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors.","volume":"16","author":"Moyle","year":"2002","journal-title":"AIDS"},{"key":"R87-36-20250312","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/00002030-200104130-00007","article-title":"Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy.","volume":"15","author":"John","year":"2001","journal-title":"AIDS"},{"key":"R88-36-20250312","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1097\/00002030-200211220-00033","article-title":"Gonzalez, et al. Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analogues.","volume":"16","author":"Batisse","year":"2002","journal-title":"AIDS"},{"key":"R89-36-20250312","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","article-title":"Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.","volume":"46","author":"Birkus","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R90-36-20250312","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1086\/323783","article-title":"Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with HIV infection: a report of 12 cases.","volume":"33","author":"Coghlan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R91-36-20250312","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1097\/00002030-200109070-00012","article-title":"Direct analysis of mitochondrial toxicity of antiretroviral drugs.","volume":"15","author":"Foli","year":"2001","journal-title":"AIDS"},{"key":"R92-36-20250312","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1258\/0956462001916498","article-title":"Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases.","volume":"11","author":"Ter Hofstede","year":"2000","journal-title":"Int J STD AIDS"},{"key":"R93-36-20250312","first-page":"141","article-title":"Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options.","volume":"1","author":"Brinkman","year":"1999","journal-title":"AIDS Rev"},{"key":"R94-36-20250312","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00002030-200403260-00007","article-title":"Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.","volume":"26","author":"Macias","year":"2004","journal-title":"AIDS"},{"key":"R95-36-20250312","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1089\/aid.2004.20.1293","article-title":"Advanced liver fibrosis in HIVHCV-coinfected patients on antiretroviral therapy.","volume":"20","author":"Fuster","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R96-36-20250312","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.20541","article-title":"The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection.","volume":"41","author":"Mehta","year":"2005","journal-title":"Hepatology"},{"key":"R97-36-20250312","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1542-3565(04)00129-6","article-title":"Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection.","volume":"2","author":"Sterling","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R99-36-20250312","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0140-6736(03)14844-1","article-title":"Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.","volume":"362","author":"Qurishi","year":"2003","journal-title":"Lancet"},{"key":"R100-36-20250312","first-page":"177","article-title":"Severe liver disease associated with prolonged exposure to antiretroviral drugs.","volume":"42","author":"Maida","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R101-36-20250312","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/135965350801300111","article-title":"Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome.","volume":"13","author":"Maida","year":"2008","journal-title":"Antivir Ther"},{"key":"R102-36-20250312","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/QAD.0b013e3280119e47","article-title":"Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients.","volume":"21","author":"Mallet","year":"2007","journal-title":"AIDS"},{"key":"R103-36-20250312","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1097\/QAD.0b013e3281e7ed64","article-title":"Response to Mallet et al., Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients.","volume":"21","author":"Garvey","year":"2007","journal-title":"AIDS"},{"key":"R104-36-20250312","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1097\/QAD.0b013e328235a54c","article-title":"Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect?","volume":"21","author":"Sandrine","year":"2007","journal-title":"AIDS"},{"key":"R105-36-20250312","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/QAD.0b013e3280fa81cb","article-title":"Nodular regenerative hyperplasia of liver as a consequence of ART.","volume":"21","author":"Arey","year":"2007","journal-title":"AIDS"},{"key":"R106-36-20250312","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1111\/j.1572-0241.2007.01428.x","article-title":"Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV.","volume":"102","author":"Schiano","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R107-36-20250312","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.cgh.2008.04.023","article-title":"Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection.","volume":"6","author":"Saifee","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R109-36-20250312","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1086\/603559","article-title":"Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.","volume":"49","author":"Kovari","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R110-36-20250312","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(00)04579-7","article-title":"Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.","volume":"357","author":"Carr","year":"2001","journal-title":"Lancet"},{"key":"R111-36-20250312","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3748\/wjg.14.185","article-title":"Non-alcoholic fatty liver disease and the metabolic syndrome: an update.","volume":"14","author":"Rector","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R112-36-20250312","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/hep.22665","article-title":"Liver damage underlying unexplained aminotransferase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy.","volume":"49","author":"Ingiliz","year":"2009","journal-title":"Hepatology"},{"key":"R113-36-20250312","first-page":"373","article-title":", Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients.","volume":"43","author":"McGovern","year":"2006","journal-title":"lin Infect Dis"},{"key":"R114-36-20250312","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/01.aids.0000163935.99401.25","article-title":"Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus.","volume":"19","author":"Sulkowski","year":"2005","journal-title":"AIDS"},{"key":"R115-36-20250312","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jhep.2008.01.015","article-title":"Hepatic steatosis in HIVHCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study.","volume":"48","author":"Rodriguez-Torres","year":"2008","journal-title":"J Hepatol"},{"key":"R116-36-20250312","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2036.2009.03995.x","article-title":"Influence of insulin resistance on hepatic fibrosis and steatosis in HCV monoinfected compared with HIV-HCV co-infected patients.","volume":"30","author":"Halfon","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R117-36-20250312","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1177\/135965350801300801","article-title":"HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3.","volume":"13","author":"Borghi","year":"2008","journal-title":"Antivir Ther"},{"key":"R118-36-20250312","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/589294","article-title":"Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.","volume":"47","author":"Guaraldi","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R119-36-20250312","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/01.aids.0000210606.63138.f5","article-title":"Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors.","volume":"20","author":"Bani-Sadr","year":"2006","journal-title":"AIDS"},{"key":"R120-36-20250312","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/QAI.0b013e318042e1db","article-title":"Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hepatitis virales CO3 Aquitaine Cohort.","volume":"45","author":"Neau","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R121-36-20250312","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1023\/A:1007649815992","article-title":"Hepatotoxicity due to mitochondrial dysfunction.","volume":"15","author":"Pessayre","year":"1999","journal-title":"Cell Biol Toxicol"},{"key":"R122-36-20250312","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2001-12927","article-title":"Etiopathogenesis of nonalcoholic steatohepatitis.","volume":"21","author":"Chitturi","year":"2001","journal-title":"Semin Liver Dis"},{"key":"R123-36-20250312","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.tiv.2008.01.011","article-title":"High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes.","volume":"22","author":"Igoudjil","year":"2008","journal-title":"Toxicol In Vitro"},{"key":"R124-36-20250312","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.aids.0000206503.01536.11","article-title":"Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients.","volume":"20","author":"Lemoine","year":"2006","journal-title":"AIDS"},{"key":"R125-36-20250312","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/MEG.0b013e328305b9e0","article-title":"Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis.","volume":"20","author":"Akhtar","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R126-36-20250312","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/hep.20519","article-title":"Impact of steatosis on progression of fibrosis in patients with mild hepatitis.","volume":"41","author":"Fartoux","year":"2005","journal-title":"Hepatology"},{"key":"R127-36-20250312","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jhep.2003.11.004","article-title":"The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.","volume":"40","author":"Patton","year":"2004","journal-title":"J Hepatol"},{"key":"R128-36-20250312","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/jhep.2001.24432","article-title":"Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.","volume":"33","author":"Adinolfi","year":"2001","journal-title":"Hepatology"},{"key":"R129-36-20250312","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/gut.52.2.288","article-title":"Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.","volume":"52","author":"Castera","year":"2003","journal-title":"Gut"},{"key":"R130-36-20250312","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0166-3542(03)00005-6","article-title":"Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks.","volume":"58","author":"Biesecker","year":"2003","journal-title":"Antiviral Res"},{"key":"R131-36-20250312","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(05)60266-8","article-title":"Riboflavin to treat nucleoside analogue-induced lactic acidosis.","volume":"352","author":"Fouty","year":"1998","journal-title":"Lancet"},{"key":"R132-36-20250312","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/jac\/dkp446","article-title":"Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.","volume":"65","author":"Vispo","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R133-36-20250312","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s12325-009-0072-z","article-title":"Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status.","volume":"26","author":"Stein","year":"2009","journal-title":"Adv Ther"},{"key":"R134-36-20250312","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(01)06042-1","article-title":"Metformin in non-alcoholic steatohepatitis.","volume":"358","author":"Marchesini","year":"2001","journal-title":"Lancet"},{"key":"R135-36-20250312","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2036.2004.01888.x","article-title":"Metformin in the treatment of patients with non-alcoholic steatohepatitis.","volume":"19","author":"Uygun","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R136-36-20250312","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1872-034X.2007.00215.x","article-title":"Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis.","volume":"38","author":"De Oliveira","year":"2008","journal-title":"Hepatol Res"},{"key":"R137-36-20250312","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2036.2008.03723.x","article-title":"Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.","volume":"28","author":"Idilman","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R138-36-20250312","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2036.2008.03869.x","article-title":"Clinical trial: pilot study of metformin for the treatment of nonalcoholic steatohepatitis.","volume":"29","author":"Loomba","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R139-36-20250312","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1572-0241.2001.03553.x","article-title":"A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.","volume":"96","author":"Caldwell","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R140-36-20250312","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"R141-36-20250312","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"R142-36-20250312","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial.","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"R143-36-20250312","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1258\/ijsa.2009.009038","article-title":"Hepatic encephalopathy as an unusual late complication of transjugular intrahepatic portosystemic shunt insertion for noncirrhotic portal hypertension caused by nodular regenerative hyperplasia in an HIV-positive patient on highly active antiretroviral therapy.","volume":"21","author":"Ding","year":"2010","journal-title":"Int J STD AIDS"},{"key":"R144-36-20250312","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/lt.21493","article-title":"A new indication for liver transplantation: nodular regenerative hyperplasia in human immunodeficiency virus-infected patients.","volume":"14","author":"Tateo","year":"2008","journal-title":"Liver Transpl"},{"key":"R145-36-20250312","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-230X-10-6","article-title":"Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient.","volume":"10","author":"Bihl","year":"2010","journal-title":"BMC Gastroenterol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.23716","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201009000-00036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T11:02:02Z","timestamp":1741777322000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201009000-00036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":116,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.23716","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}